CERo Therapeutics (NASDAQ:CERO) Upgraded at D. Boral Capital

D. Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO) from a hold rating to a buy rating in a research report report published on Monday morning, Marketbeat.com reports. The brokerage currently has $30.00 target price on the stock.

CERO has been the subject of several other research reports. D Boral Capital downgraded shares of CERo Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 30th. Maxim Group began coverage on shares of CERo Therapeutics in a research report on Monday, May 19th. They set a “buy” rating and a $60.00 price objective for the company.

CERo Therapeutics Stock Up 17.1%

Shares of NASDAQ:CERO opened at $11.19 on Monday. CERo Therapeutics has a 52 week low of $6.71 and a 52 week high of $895.40. The company has a 50 day moving average price of $12.14 and a two-hundred day moving average price of $39.09.

CERo Therapeutics (NASDAQ:CERO) last issued its earnings results on Thursday, May 15th. The company reported ($31.80) EPS for the quarter.

Institutional Investors Weigh In On CERo Therapeutics

Several large investors have recently made changes to their positions in the stock. Armistice Capital LLC bought a new stake in shares of CERo Therapeutics during the first quarter worth $228,000. Parallel Advisors LLC acquired a new position in CERo Therapeutics during the first quarter worth $161,000. ARCH Venture Management LLC boosted its holdings in CERo Therapeutics by 550.4% during the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock worth $564,000 after purchasing an additional 7,949,265 shares during the last quarter. Finally, Avantax Planning Partners Inc. boosted its holdings in CERo Therapeutics by 89.9% during the fourth quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock worth $155,000 after purchasing an additional 1,224,021 shares during the last quarter. Institutional investors own 29.64% of the company’s stock.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.